Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M51.3Revenue (TTM) $M--Net Margin (%)--Altman Z-Score4.7
Enterprise Value $M47.9EPS (TTM) $-0.2Operating Margin %--Piotroski F-Score2
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yY
Price/Book1.310-y EBITDA Growth Rate %--Quick Ratio15.2Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio15.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-24.1Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-26.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M56.4ROIC % (ttm)-45.3Gross Margin Increase y-yN

Gurus Latest Trades with BLRX

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

BLRX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


BLRX: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about BLRX:

    News about BLRX:

    Articles On GuruFocus.com
    Analysts Positive on BioLineRx Ltd. Following Ph2 Testing Expansion for AML May 05 2015 
    Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 

    More From Other Websites
    BioLineRx and I-Bridge Capital Establish a New Drug Development Joint Venture in China Aug 25 2016
    7:04 am BioLineRx establishes JV with I-Bridge Capital, a Chinese venture capital fund focused on... Aug 25 2016
    BioLineRx and I-Bridge Capital Establish a New Drug Development Joint Venture in China Aug 25 2016
    BioLineRx downgraded by Maxim Group Aug 12 2016
    BioLineRx Names Philip A. Serlin as Chief Executive Officer Aug 11 2016
    BioLineRx Reports Second Quarter 2016 Financial Results Aug 11 2016
    BioLineRx Reports Second Quarter 2016 Financial Results Aug 11 2016
    BioLineRx Names Philip A. Serlin as Chief Executive Officer Aug 11 2016
    BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination... Aug 08 2016
    BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination... Aug 08 2016
    BioLineRx to Report Second Quarter Results on August 11, 2016 Aug 04 2016
    BioLineRx to Report Second Quarter Results on August 11, 2016 Aug 04 2016
    BioLineRx Announces In-licensing of Liver Fibrosis Project Under Strategic Collaboration Aug 01 2016
    BioLineRx Announces In-licensing of Liver Fibrosis Project Under Strategic Collaboration Aug 01 2016
    BioLineRx Announces Regulatory Submissions for Phase 2a Trial of BL-8040 in Combination with... Jun 28 2016
    BioLineRx to Present at the JMP Securities Life Sciences Conference in New York Jun 15 2016
    BioLineRx to Present at the JMP Securities Life Sciences Conference in New York Jun 15 2016
    BioLineRx's BL-8040 to be Presented at Upcoming Scientific Conferences May 19 2016
    BioLineRx's BL-8040 to be Presented at Upcoming Scientific Conferences May 19 2016
    BioLineRx Reports First Quarter 2016 Financial Results May 17 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)